MBC Pharma, Inc. is a biopharmaceutical company focused on discovering and developing drugs for bone diseases such as cancer and osteoporosis. MBC Pharma's comprehensive and patented technology enables the highly efficient and specific delivery of drugs to bone. MBC Pharma's technology improves upon the existing efficacy of clinically successful therapies. The approach has yielded promising lead structures in preclinical development for the treatment of multiple myeloma, metastatic bone disease caused by breast, prostate and lung cancer as well as osteoporosis and osteopenia.

MBC Pharma is focused on the bone disease market. This area of therapeutic focus is important for the following reasons:

• Large Markets with High Growth Potential
  • Osteoporosis is a very serious health concern that primarily affects post-menopausal women and, due to the aging population trend, dramatic growth in this market will occur for decades to come. Furthermore, only a small fraction of those who could benefit from therapy are currently taking antiresorptive drugs. It is estimated that there are currently 44 million Americans at risk of or suffering from osteoporosis.
    
    
  • Cancer caused rates of death and the levels of associated morbidity have remained basically unchanged for 50 years. Metastatic bone disease in breast, prostate and lung cancer is of particular concern and these happen to be the three most prevalent cancers. The American Cancer Society estimates that in 2004 in the US alone there was over 213,000 new cases of breast cancer diagnosed and about 41,000 deaths. The combined deaths from breast, prostate and lung cancer totaled over 231,000 last year. Bone involvement is seen in over 50% of cases and virtually all patients who die from these cancers have bone metastases.

• Clear Need for New and Effective Drugs

While bone health is an area of intense competition, the drugs currently available to treat osteoporosis all have significant disadvantages that demonstrate the need for a well-tolerated and effective new therapy. Inconvenient dosing regimens and insidious side effects and risks are associated with available osteoporosis drugs; our approach addresses these physician and patient concerns alike. Furthermore, the ability to effectively treat bone metastases with current systemic chemotherapies leaves much to be desired. Metastatic lesions on bone, and the resulting bone weakening, vulnerability to skeletal fractures and severe bone pain are significant contributors to the reduced quality of life of cancer patients. Essentially 100% of patients who die from breast, prostate or lung cancer have bone metastases and presentation with bone metastases is correlated with shorter survival. The ability to complement existing therapies with a drug which effectively targets bone lesions while presenting few or no additional side effects is of great value to the patient, the physician and the marketplace.